{"id":"NCT00266799","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)","officialTitle":"A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (PELICAN Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01-13","primaryCompletion":"2010-09-29","completion":"2010-10-18","firstPosted":"2005-12-19","resultsPosted":"2011-11-16","lastUpdate":"2017-06-08"},"enrollment":210,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Pegylated liposomal doxorubicin (SCH 200746)","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":[]}],"arms":[{"label":"Pegylated liposomal doxorubicin","type":"EXPERIMENTAL"},{"label":"Capecitabine","type":"ACTIVE_COMPARATOR"}],"summary":"This is an open-label, multinational, randomized, multicenter trial designed to compare pegylated liposomal doxorubicin with capecitabine as first line chemotherapy of metastatic breast cancer. The primary objective of the study is to compare the time to disease progression, although overall response rates, overall survival, quality of life, time to treatment failure, and safety and tolerability will also be assessed.","primaryOutcome":{"measure":"Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST)","timeFrame":"From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death","effectByArm":[{"arm":"Pegylated Liposomal Doxorubicin (PLD)","deltaMin":6.02,"sd":null},{"arm":"Capecitabine","deltaMin":6.05,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6686"},{"comp":"OG000 vs OG001","p":"0.4472"},{"comp":"OG000 vs OG001","p":"0.5508"},{"comp":"OG000 vs OG001","p":"0.4088"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":23},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["34037241"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":98},"commonTop":["PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME","FATIGUE","NAUSEA","EAR, NOSE AND THROAT EXAMINATION ABNORMAL","DIARRHOEA"]}}